Trending Topic

Illustration of the thought processes in the brain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% to exceeding 15% per 5 years.3 Ruptured IA is the primary aetiology of […]

ECTRIMS 2017 – Mark Freedman Interview – Part 1

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 3rd 2017

Mark Freedman discusses recent developments and unmet needs in MS. Part 1 of 2.

View Part 2 here.

1. What have been the most significant recent developments in MS? (0:05)
2. Discuss the current unmet needs and/or the challenges you face as an MS specialist (1:05)

Speaker disclosures: Mark Freedman has received honoraria or consultation fees from Bayer Healthcare, Biogen-Idec, Chugai, EMD Canada, Genzyme, Novartis, Sanofi-Aventis and Teva Canada Innovation. He is a member of the following company advisory boards, board of directors or other similar group for Bayer Healthcare, Biogen-Idec, Hoffman La-Roche, Merck Serono, Novartis, Opexa and Sanofi-Aventis. He is a participant in Genzyme’s company-sponsored speaker’s bureau.

Filmed at the 7th Joint ECTRIMS-ACTRIMS Meeting, Paris, France, October 2017.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup